このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Phase III Study of WSD0922-FU Versus Chemotherapy In Patients With C797S+ Advanced Non-small Cell Lung Cancer (WAYWIN-301)

2026年11月13日 更新者:Wayshine Biopharm, Inc.

An Open-label, Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of WSD0922-FU Monotherapy Versus Platinum-based Doublet Chemotherapy in Participants With EGFR C797S Mutation-positive, Locally Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy.

This is an Open-label, Randomized, Controlled, Multicenter Phase III Study Evaluating Efficacy and Safety of WSD0922-FU Monotherapy versus Platinum-based Doublet Chemotherapy for Participants with EGFR C797S Mutation-positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy

調査の概要

状態

まだ募集していません

条件

介入・治療

研究の種類

介入

入学 (推定)

196

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200123
        • Shanghai East Hospital
        • コンタクト:
        • 主任研究者:
          • Caicun Zhou, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Histologically or cytologically confirmed locally advanced or metastatic NSCLC
  2. Eligible for platinum-based doublet chemotherapy
  3. Prior first-line treatment with monotherapy of third-generation EGFR-TKIs (osimertinib, Firmonertinib, Almonertinib, etc.) or third-generation EGFR-TKIs combined with anti-angiogenic drugs or Lazertinib combined with Amivantamab, confirmed by imaging evidence of disease progression, and no other systemic antitumor therapy was administered after progression
  4. Tissue sample confirmed C797S positive by central lab using NGS
  5. At least one measurable target lesion per RECIST v1.1 criteria
  6. ECOG 0-1
  7. Adequate organ function and bone marrow function
  8. Women should take appropriate contraceptive measures and should not breastfeed. If they have fertility, they must undergo a negative pregnancy test before starting medication
  9. Male participants should agree to the use of contraceptive measures

Exclusion Criteria:

  1. Presence of clear bypass tumor driver (e.g., KRAS activating mutations, Braf V600E, MET exon 14 skipping, HER2 mutations, RET fusion, ROS1 fusion etc.)
  2. Histological or phenotypic transformation
  3. Any severe or uncontrolled systemic disease
  4. ≥ Grade 2 toxicities per CTCAE v6.0 attributed to prior anti-tumor therapy except hearing loss, hair loss, and fatigue
  5. Participants with leptomeningeal, brainstem, or spinal cord metastases and/or spinal cord compression, as well as active brain metastases, increased intracranial pressure or associated risks (such as intracranial hemorrhage or intracranial infection), or symptomatic cerebral complications requiring urgent neurosurgical or pharmacological (e.g., mannitol) intervention
  6. A history of interstitial lung disease (ILD), drug-induced ILD, or non-infectious pneumonitis requiring steroid treatment; or suspected ILD or non-infectious pneumonitis that can't be ruled out by imaging at the time of screening
  7. Clinically significant cardiac abnormalities or severe/uncontrolled/active cardiovascular disease
  8. Significant clinical bleeding tendency or history of severe arterial/venous thromboembolic events
  9. Poorly controlled diabetes mellitus or hypertension
  10. History of other primary malignancies within two years
  11. Known active or suspected autoimmune diseases; or known active ocular diseases (such as active wet age-related macular degeneration, diabetic retinopathy with macular edema)
  12. Active infectious diseases (e.g., active HIV, HBV and HCV)
  13. Known alcohol or drug dependence
  14. Mental disorders or poor compliance
  15. The investigator believes that the subject has other reasons that make them unsuitable for participating in this clinical study

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:WSD0922-FU Tablet

Participants will take WSD0922-FU 120 mg BID under fasted condition, administered orally; treatment cycles are 21 days in duration, continuing until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation

他の名前:
  • WSD0922
アクティブコンパレータ:Platinum-Based Doublet Chemotherapy

Participants will receive 4 cycles of standard platinum-based doublet chemotherapy (selected by the investigator based on participant's condition and tolerance):

Option 1: Pemetrexed 500 mg/m² IV infusion + Cisplatin 75 mg/m² IV infusion on Day 1 of each 21-day cycle.

Option 2: Pemetrexed 500 mg/m² IV infusion + Carboplatin AUC 5 IV infusion on Day 1 of each 21-day cycle.

Followed by maintenace of Pemetrexed 500 mg/m² IV infusion until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation

他の名前:
  • シスプラチン
  • カルボプラチン
  • ペメトレキセド
  • Platinum-based doublet chemotherapy

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Progression Free Survival (PFS)
時間枠:From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.

PFS as assessed by Blinded independent Central Review (BICR) per RECIST 1.1

From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall Survival (OS)
時間枠:From the date of randomization to the date of death from any cause, assessed up to 36 months.

OS

From the date of randomization to the date of death from any cause, assessed up to 36 months.

その他の成果指標

結果測定
メジャーの説明
時間枠
PFS as assessed by investigator per RECIST 1.1
時間枠:From date of randomization until the date of investigator confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
From date of randomization until the date of investigator confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Objective Response Rate (ORR)
時間枠:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

ORR as assessed by investigator and BICR per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Duration of Response (DOR)
時間枠:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

DoR by BICR and Investigator per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Disease Control Rate (DCR)
時間枠:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

DCR by BICR and Investigator per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Time to Disease Progression (TTP)
時間枠:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

TTP by BICR and Investigator per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Time to Response (TTR)
時間枠:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

TTR by BICR and Investigator per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial ORR (icORR)
時間枠:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icORR by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial PFS (icPFS)
時間枠:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icPFS by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial DOR (icDOR)
時間枠:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icDOR by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial DCR (icDCR)
時間枠:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icDCR by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial TTP (icTTP)
時間枠:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icTTP by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial TTR (icTTR)
時間枠:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icTTR by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
AE and SAE
時間枠:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

AE and SAE per CTCAE 6.0

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30
時間枠:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

Quality of life according to the EORTC QLQ-C30 test results from a minimum of 0 to a maximum of 100, where higher scores represent either a better or worse outcome depending on the specific subscale

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13
時間枠:From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

Quality of life according to the EORTC QLQ-LC13 test results from a minimum of 0 to a maximum of 100, where higher scores indicate a worse outcome

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Caicun Zhou, MD、Shanghai East Hospital

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月10日

一次修了 (推定)

2028年5月1日

研究の完了 (推定)

2029年10月31日

試験登録日

最初に提出

2026年11月8日

QC基準を満たした最初の提出物

2026年11月13日

最初の投稿 (実際)

2026年11月19日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月19日

QC基準を満たした最後の更新が送信されました

2026年11月13日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。